Endothelial progenitor cells for vascular regeneration.

The basis for native as well as therapeutic neovascularization is not restricted to angiogenesis but includes postnatal vasculogenesis. Our laboratory and others' have established that bone marrow-derived endothelial progenitor cells (EPCs) are present in the systemic circulation, are augmented in response to certain cytokines and/or tissue ischemia, and home to as well as incorporate into sites of neovascularization. Given the background, EPCs have been investigated as therapeutic agents in these studies of supply-side angiogenesis under pathological as well as physiological conditions. This review discusses the therapeutic potential of EPCs for cardiovascular ischemic diseases.

[1]  A M Zeiher,et al.  HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. , 2001, The Journal of clinical investigation.

[2]  J. Isner,et al.  HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells. , 2001, The Journal of clinical investigation.

[3]  S. Fichtlscherer,et al.  Increase in Circulating Endothelial Progenitor Cells by Statin Therapy in Patients With Stable Coronary Artery Disease , 2001, Circulation.

[4]  T. Murohara,et al.  Mobilization of Endothelial Progenitor Cells in Patients With Acute Myocardial Infarction , 2001, Circulation.

[5]  S. Homma,et al.  Neovascularization of ischemic myocardium by human bone-marrow–derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function , 2001, Nature Medicine.

[6]  J. Isner,et al.  Therapeutic Potential of Ex Vivo Expanded Endothelial Progenitor Cells for Myocardial Ischemia , 2001, Circulation.

[7]  S. Rafii,et al.  Vascular Trauma Induces Rapid but Transient Mobilization of VEGFR2+AC133+ Endothelial Precursor Cells , 2001, Circulation research.

[8]  I. Shiojima,et al.  The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. , 2000, Nature Medicine.

[9]  J. Isner,et al.  VEGF gene transfer mobilizes endothelial progenitor cells in patients with inoperable coronary disease. , 2000, The Annals of thoracic surgery.

[10]  J. Isner,et al.  Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. , 2000, Circulation research.

[11]  K. Pantel,et al.  In vitro differentiation of endothelial cells from AC133-positive progenitor cells , 2000 .

[12]  S. Dirnhofer,et al.  Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells , 2000, The Lancet.

[13]  J. Isner,et al.  Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[14]  S. Rafii,et al.  Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. , 2000, Blood.

[15]  J. Isner,et al.  Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. , 1999, Circulation research.

[16]  J. Isner,et al.  VEGF contributes to postnatal neovascularization by mobilizing bone marrow‐derived endothelial progenitor cells , 1999, The EMBO journal.

[17]  J. Isner,et al.  Impaired collateral vessel development associated with reduced expression of vascular endothelial growth factor in ApoE-/- mice. , 1999, Circulation.

[18]  J. Garcia,et al.  Human cord blood CD34+CD38- cell transduction via lentivirus-based gene transfer vectors. , 1999, Human gene therapy.

[19]  Hiroshi Takahashi,et al.  Enhanced inhibition of hepatitis B virus production by asialoglycoprotein receptor-directed interferon , 1999, Nature Medicine.

[20]  Haruchika Masuda,et al.  Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization , 1999, Nature Medicine.

[21]  J. Isner,et al.  Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. , 1999, The American journal of pathology.

[22]  J. Isner,et al.  Age-dependent impairment of angiogenesis. , 1999, Circulation.

[23]  J. Isner,et al.  Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. , 1998, Journal of vascular surgery.

[24]  R. Sidman,et al.  Engraftable human neural stem cells respond to development cues, replace neurons, and express foreign genes , 1998, Nature Biotechnology.

[25]  S. Rafii,et al.  Evidence for circulating bone marrow-derived endothelial cells. , 1998, Blood.

[26]  J. Folkman,et al.  Isolation and characterization of endothelial progenitor cells from mouse embryos. , 1998, Development.

[27]  J. Isner,et al.  Hypercholesterolemia attenuates angiogenesis but does not preclude augmentation by angiogenic cytokines. , 1997, Circulation.

[28]  Takayuki Asahara,et al.  Isolation of Putative Progenitor Endothelial Cells for Angiogenesis , 1997, Science.

[29]  M. Petch,et al.  Aging-associated endothelial dysfunction in humans is reversed by L-arginine. , 1996, Journal of the American College of Cardiology.

[30]  T. Lüscher,et al.  Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery. , 1996, The Journal of clinical investigation.

[31]  Kenneth J. Hillan,et al.  Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.

[32]  Lieve Moons,et al.  Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.

[33]  M. Creager,et al.  Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans. , 1996, Hypertension.

[34]  S. Heimfeld,et al.  Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. , 1995, The New England journal of medicine.

[35]  Janet Rossant,et al.  Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice , 1995, Nature.

[36]  L. Ghiadoni,et al.  Aging and endothelial function in normotensive subjects and patients with essential hypertension. , 1995, Circulation.

[37]  M. Creager,et al.  Impaired Endothelium‐Dependent Vasodilation in Patients With Insulin‐Dependent Diabetes Mellitus , 1993, Circulation.

[38]  W. Risau,et al.  Induction of vasculogenesis and hematopoiesis in vitro. , 1992, Development.

[39]  R. M. Fox,et al.  Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy , 1992, The Lancet.

[40]  H. Drexler,et al.  Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine , 1991, The Lancet.

[41]  J. Armitage,et al.  The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. , 1991, Blood.

[42]  C D Marsden,et al.  Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. , 1990, Science.

[43]  L. Pardanaud,et al.  Relationship between vasculogenesis, angiogenesis and haemopoiesis during avian ontogeny. , 1989, Development.

[44]  T. Doetschman,et al.  Vasculogenesis and angiogenesis in embryonic-stem-cell-derived embryoid bodies. , 1988, Development.

[45]  J. Glowacki,et al.  Engraftment of a clonal bone marrow stromal cell line in vivo stimulates hematopoietic recovery from total body irradiation. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[47]  J Folkman,et al.  Transplacental carcinogenesis by stilbestrol. , 1971, The New England journal of medicine.

[48]  R. Hebbel,et al.  Origins of circulating endothelial cells and endothelial outgrowth from blood. , 2000, The Journal of clinical investigation.

[49]  T. Lüscher,et al.  Endothelial dysfunction in diabetes mellitus. , 1998, Journal of cardiovascular pharmacology.

[50]  K. Rajewsky,et al.  Perspectives Series: Molecular Medicine in Genetically Engineered Animals , 1996 .

[51]  E. Shpall,et al.  Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  T. Lüscher,et al.  Endothelial dysfunction in coronary artery disease. , 1993, Annual review of medicine.